Abbreviations & Acronyms CIS = carcinoma in situ FSA = frozen section assessment MRI = magnetic resonance imaging NA = not available NVB = neurovascular bundle PSA = prostate-specific antigen RCC = renal cell carcinoma RP = radical prostatectomy SM = surgical margin Abstract: Despite significant advances in patient selection as well as surgical technique over the past few decades, it is still not uncommon for patients with urological malignancy and positive surgical margins to be observed. Meanwhile, intraoperative pathology consultation with frozen section assessment, which generally provides useful information for the optimal procedure, has been widely utilized for the assessment of surgical margins during urological surgeries. Thus, it remains unanswered whether intraoperative frozen section assessment has an impact on final surgical margin status as well as long-term oncological outcomes. The present review summarizes and discusses available data assessing the utility of frozen section assessment of the surgical margins during urological surgeries, such as radical prostatectomy, partial nephrectomy and radical cystectomy. The current findings suggest that select patients might benefit from the routine frozen section assessment.
Introduction
Considerable improvements have been made in the technique of urological surgery. Nevertheless, positive surgical margins, which have generally been believed to be a poor prognostic factor, are not uncommonly seen, even in specimens from recent surgeries, especially for high-risk diseases (e.g. up to 49% after robot-assisted radical prostatectomy, up to 26% after robot-assisted radical cystectomy). 1, 2 Meanwhile, in some studies, it has been documented that the status of surgical margins in curative resection does not significantly affect long-term oncological outcomes. [3] [4] [5] Common indications for intraoperative consultation in surgical pathology include histological diagnosis (e.g. non-neoplastic vs neoplastic, benign vs malignant, histological subtype) of masses incidentally found or enlarged lymph nodes. In these instances, FSA of the biopsy or resection specimen often provides critical information for appropriate surgical procedure. Similarly, FSA of the sentinel lymph node has been found to be useful for staging the primary tumor and deciding whether the surgeon proceeds with radical surgery, such as prostatectomy for prostate cancer. 6, 7 Additionally, it has been documented that, in patients with testicular germ cell tumor undergoing chemotherapy, limited versus extensive retroperitoneal lymph node dissection can be safely carried out based on FSA findings (i.e. necrosis or fibrosis vs teratoma or viable tumor), 8, 9 although intraoperative consultation might not be routinely requested in this setting. 10 FSA of the surgical margins, while it is one of the most challenging fields in diagnostic surgical pathology practice, has also been widely utilized with the aim to ensure complete resection of the tumor. In general, when the FSA is positive for tumor, additional tissue is excised until a negative FSA at the site is achieved. Furthermore, FSA diagnosis is often correlated with the status of the final surgical margin. However, it remains controversial whether intraoperative FSA truly contributes to: (i) reducing the risk of positive surgical margins in the final resection specimen; and (ii) subsequently improving the prognosis of patients. Previous review articles have mainly focused on the accuracy and pitfalls of FSA diagnosis essentially described for pathologists. [10] [11] [12] The main objective of the current review was to evaluate the utility of routine FSA during urological surgeries, such as radical prostatectomy, partial nephrectomy and radical cystectomy, in the final surgical margin status as well as long-term oncological outcomes.
FSA of surgical margins during prostatectomy
Recent progress in preoperative assessment through imaging modalities and nomograms have led to relatively precise prediction of tumor extent, as well as selection of the patients suitable for radical prostatectomy. However, occasional positive surgical margins after radical prostatectomy are mainly derived from unexpected extension of the tumor. Because the margin status in radical prostatectomy specimens is considered to be a crucial prognosticator for biochemical recurrence, intraoperative pathology consultation is often requested to evaluate surgical margins. A biopsy from the area of the neurovascular bundles may particularly be submitted for FSA when a nerve-sparing procedure is attempted. Of note, there is currently no clear consensus as to patient selection, as well as the appropriate site of margin tissue and the number of the specimens sampled for FSA.
Previous studies without the control cohort of no FSA in radical prostatectomy have shown the potential benefits of intraoperative pathology consultation not only when positive margins are suspected, but also when requested routinely at specific prostatic sites where positive margins are often seen (e.g. urethral stump next to the apex, dorsolateral area of the neurovascular bundles). 13 In contrast, because of the difficulty in diagnosing prostatic adenocarcinoma on FSA specimens, there are risks of false positive and false negative surgical margins. Additionally, in some of the cases (e.g. 8.1-9.1% of initial FSA-positive cases), especially with extensive tumor, positive surgical margins could be identified on radical prostatectomy specimens at the sites where FSA was not carried out. 14, 15 Recent comparative studies have further assessed the utility of FSA of the surgical margins during radical prostatectomy, with mixed results (Table 1) . One of the first comparative studies after 2000 showed that 26.7% of radical prostatectomy specimens with FSA carried out at the neurovascular bundle were positive for a final surgical margin, which was significantly (P = 0.013) higher than its rate (13.8%) in the cohort of no FSA. 16 Similar findings were obtained in even a smaller study: 34.8% of FSA cases versus 7.1% of no-FSA cases showed positive surgical margins in prostatectomy specimens, although the difference was not statistically significant (P = 0.054). 17 These unfavorable data for intraoperative FSA were most likely due to a selection bias (e.g. more aggressive tumor characteristics or larger tumor volume in the FSA cohort). In contrast, a larger study showed that FSA at the neurovascular bundle significantly (P < 0.001) reduced the incidence of positive surgical margin (15.2%) in 2567 radical prostatectomies, compared with the same number of propensity score-matched cases without FSA (21.7%). 18 A more recent study in which magnetic resonance imagingdirected FSA was carried out during radical prostatectomy and all 18 initial FSA-positive cases achieved negative conversion in subsequent FSA(s) at the same site confirmed a significant improvement in the rate of final positive surgical margins by intraoperative pathology consultation (7.5% in the FSA cohort vs 18.7% in the age/PSA/stage-matched controls, P = 0.010). 19 In other studies with 20 or without 21 the potential selection bias, there was no statistically significant difference in final surgical margin positivity between radical prostatectomies with versus without intraoperative FSA.
I have reported our experience in radical prostatectomies with (n = 1128) and without (n = 1480) intraoperative FSA assessing surgical margins. 15 Overall, 9.7% of FSA cases versus 11.0% of no-FSA cases were found to have positive surgical margins on prostatectomy specimens. Thus, FSA did not considerably reduce the incidence of positive margin (P = 0.264), whereas patients undergoing FSA had a significantly higher Gleason score on biopsy (P = 0.007) and pathological pT stage on prostatectomy (P = 0.043) compared with control patients. Nevertheless, when compared in the subgroups according to histopathological features including Gleason score on biopsy and Gleason score, pT stage, pN stage, or cancer volume on prostatectomy, there were statistically significant differences in the rate of final positive surgical margin in prostatectomy specimens between FSA versus no-FSA cases showing biopsy Gleason score 7 or higher (10.1% vs 15.3%, P = 0.012) as well as 8 or higher (16.3% vs 28.6%, P = 0.048). Carrying out FSA also resulted in marginal reductions of the margin-positive rate in cases with 
To the best of my knowledge, only a few studies have assessed the impact of FSA during radical prostatectomy on patient outcomes. In a study comparing between radical prostatectomy cases with versus without FSA, carrying out FSA was associated with a marginally lower risk of biochemical recurrence after the surgery in patients with pT2 tumor (P = 0.065), but not pT3a (P = 0.168) or pT3b (P = 0.996) tumor. 18 I further analyzed our 2608-case data 15 to compare the risks of biochemical recurrence defined as a single PSA level of 0.1 ng/mL or higher after radical prostatectomy between the FSA and no-FSA cohorts (unpubl. data). No significant difference in biochemical recurrence was observed between all patients with versus without FSA (P = 0.547; Fig. 1a ), as well as between pT2 (P = 0.120), pT3a (P = 0.743) or pT3b (P = 0.751) cases with versus without FSA (figure not shown). However, there was a trend to correlate between the risk of biochemical recurrence and FSA in biopsy Gleason score 7 cases (P = 0.097; Fig. 1b ) or biopsy Gleason score 4 + 3 = 7 cases (P = 0.069; Fig. 1c ), but not that in biopsy Gleason score 6 (P = 0.437), 3 + 4 = 7 (P = 0.318), 8 (P = 0.674) or 9-10 (P = 0.209) cases. Additionally, when recurrence-free survival was stratified by the diagnosis of FSA (Fig. 1d ), patients with atypical or malignant FSA and malignant FSA had a significantly higher risk of biochemical recurrence compared with those with benign FSA (P = 0.002) and benign or atypical FSA (P = 0.006), respectively.
Various studies have assessed the utility of intraoperative FSA carried out at different sites of the prostate or periprostatic soft tissue. In some of the aforementioned studies, FSA was carried out at the dorsolateral zone/neurovascular bundles. 16, 18, 20, 21 Importantly, FSA in these areas has been shown to improve potency rates without compromising cancer controls. 22 In a series of 500 prostatectomy cases, 21 (4.5%) of 468 FSAs at the apex were positive for carcinoma, and additional tissue resection in some of these cases resulted in a decrease in the rate of positive surgical margins to 3.8%. 23 Similarly, initial positive FSA at the apex (6.1% of 198 apical biopsies) and subsequent resection in all these cases reduced the positive margin rate from 8.6% to 3.5% (P = 0.01). 24 Meanwhile, additional excision of the urethral stump has been associated with increased risks of postoperative incontinence. 25 In contrast, FSA at the bladder neck is not usually recommended, because the incidence of positive biopsies is often very low (e.g. 0.5-0.8%). 23, 24 It was noted in a study involving 73 patients that circumferential biopsies of the bladder neck after bladder neck-sparing radical prostatectomy often contained prostatic adenocarcinoma (12%), as well as non-neoplastic prostate tissue (7%). 26 In our study, we found significant reduction of a positive surgical margin rate by carrying out FSA at the apex/distal urethra (7.5%, P = 0.035), compared with that of no-FSA cases (11.0%), but not by FSA at the mid prostate including neurovascular bundles (8.8%, P = 0.289) or the base/bladder neck (9.9%, P = 0.426). 15 Thus, most of the comparative studies in a retrospective manner failed to show the overall benefit of FSA of the surgical margins at any specific sites during radical prostatectomy. However, certain populations of patients, such as those with biopsy Gleason score 7 tumor, might benefit from intraoperative FSA, especially at the distal urethra or apex of the prostate, to reduce the risk of positive surgical margins and subsequent tumor recurrence.
FSA of surgical margins during nephrectomy
Intraoperative pathology consultation is rarely requested for the assessment of the surgical margin status during radical nephrectomy for renal neoplasms, as well as nephroureterectomy for urothelial neoplasms. In contrast, it is often useful for ensuring complete tumor resection with negative surgical margins during partial nephrectomy or nephron-sparing surgery. Pathologists receive two types of margin tissues, small fragment(s) of the tumor bed and the entire specimen of a partial nephrectomy. The former is typically submitted for FSA entirely, and the presence of any tumor cells is considered as a positive surgical margin. When a partial nephrectomy specimen is received, the pathologist tries to show the renal parenchymal margin, inks and sections it perpendicularly to the margin, and usually then submits one (or more) section(s) for FSA from an area grossly closest to the tumor. Perpendicular sectioning of the partial nephrectomy specimen is also useful for measuring the distance between the tumor and the margin. In a retrospective comparison of two methods, combined gross examination of the partial nephrectomy specimen (with or without FSA) and tumor bed biopsy were found to better predict the status of final surgical margins, compared with one method alone.
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A non-systemic literature search revealed the rates of positive surgical margins in partial nephrectomy specimens, ranging 0-7.0% after open surgery, 0.7-4.0% after laparoscopic surgery and 3.9-5.7% after robot-assisted surgery, in which routine FSA was unlikely to deliver additional information of clinical significance. 28 Specifically, FSA of tumor bed biopsy often yielded unreliable results, and the biopsy specimen represented only a small fraction of the total parenchymal margin. Gross margin evaluations by the surgeons were also found to be reliable as almost equal to FSA regarding the prediction of final margin status. 29 In addition, the accuracy of FSA diagnosis during partial nephrectomy in a cohort of 301 patients was questionable, and more importantly, the results had a minimal impact on long-term oncological outcomes. 30 However, in select cases including those suspicious for positive surgical margin during gross examination, carrying out FSA was suggested to improve diagnostic accuracy. 27, 29 In a more recent study, because of the relatively high false negative rate of FSA diagnosis and inconsistency in influencing intraoperative management, as well as controversy over the prognosis of a positive surgical margin, routine use of FSA during partial nephrectomy is not recommended. 31 Several comparative studies have assessed the utility of FSA of the surgical margin during partial nephrectomy, leading to conflicting conclusions (Table 2 ). In a study involving an initial 128 patients undergoing robot-assisted partial nephrectomy with intraoperative FSA and the following 214 cases without FSA, the rates of final positive surgical margins were similar (0.8% vs 2.8%, P = 0.263), whereas operative time was even significantly longer in the no-FSA cohort (180 min vs 193 min, P = 0.04). 32 In addition, postoperative complications included in the Clavien-Dindo classification system were significantly (P = 0.03) more often seen in the FSA group (24%) than in the no-FSA group (15%). In contrast, in a total of 537 patients undergoing partial nephrectomy for renal tumors, there was a statistically significant difference in the rates of final positive surgical margin in the FSA group (4.5%) versus no-FSA group (11.0%). 33 However, the difference became statistically insignificant (2.9% vs 5.5%; P = 0.16) when compared only in patients with a malignant tumor on final pathology.
I have reported comparative data between the rates of final positive surgical margin in 300 partial nephrectomies with intraoperative FSA versus 147 partial nephrectomies without FSA. 4 There were no significant differences in clinicopathological features, including laterality, histological type and Fuhrman nuclear grade of the tumors, between the FSA and no-FSA groups, whereas FSA was more likely (P < 0.001) to be carried out for endophytic tumors (76.4%) than for exophytic tumors (61.0%), as well as during open surgeries (86.8%) than during laparoscopic surgeries (58.5%). Overall, carrying out FSA in renal cell carcinoma cases was associated with significantly fewer positive surgical margins (4.3%) than no FSA (16.7%). Interestingly, there was only a marginal difference (P = 0.089) seen in open partial nephrectomies for renal cell carcinoma. In addition, final surgical margins were less likely (P = 0.036) to be positive if more than one FSA was carried out (0.9%), compared with when only one FSA was sent (6.3%), and were more likely (P < 0.001) to be positive if FSA was positive for carcinoma (25.0%), compared with negative (2.4%) or indeterminate (0%) FSA. Carrying out FSA also resulted in a significant reduction in the rate of positive surgical margins in the following groups of patients with renal cell carcinoma undergoing partial nephrectomy laparoscopically: clear cell (16.9% ? 3.0%; P = 0.002) or papillary (15.8% ? 0%; P = 041) subtype, upper (28.6% ? 4.5%; P = 0.004) or mid (14.3% ? 0%; P = 0.002) pole tumor, either exophytic (14.8% ? 3.6%; P = 0.029) or endophytic (17.6% ? 1.7%; P = 0.014) tumor, pT1a (17.9% ? 2.6%; P < 0.001) or pT1 (15.4% ? 2.2%; P < 0.001) tumor, or Fuhrman grade 1-2 (15.0% ? 2.2%; P = 0. The majority of the aforementioned studies did not assess the role of FSA in patient outcomes. In our study, KaplanMeier and log-rank tests in all renal cell carcinoma cases showed that carrying out FSA did not considerably improve recurrence-free survival (P = 0.114). 4 However, FSA was associated with significantly improved recurrence-free survival in patients undergoing laparoscopic partial nephrectomy for exophytic tumors (P = 0.011), but not endophytic tumors (P = 0.912), or for pT1 tumors (P = 0.004), but not ≥pT2 tumors (P = 335). No impact of FSA on recurrence-free survival was obtained in patients undergoing laparoscopic partial nephrectomy subgrouped according to tumor location, histological type or Fuhrman grade, with marginal significance in clear cell renal cell carcinoma cases (P = 0.061), as well as in those undergoing open surgery.
Thus, there are only a few studies that have compared the cases with versus without FSA, whereas other studies of partial nephrectomy have mainly assessed the accuracy of FSA or the rate of positive surgical margins only in patients undergoing FSA. 34 In general, FSA appears to have greater utility in laparoscopic partial nephrectomies compared with open partial nephrectomies. In these comparative studies, however, neither FSA nor surgical margin status was shown to significantly affect tumor recurrence. 4, 32, 33 Instead, there might be a role for FSA in select groups of patients who have, for instance, ≤4-cm and/or exophytic tumor.
FSA of surgical margins during cystectomy
Two types of surgical margin tissues are commonly submitted for intraoperative pathology consultation during cystectomy for bladder cancer: entire partial resection specimens, and biopsy specimens of the ureter, urethra, and, in rare cases, perivesical soft tissue. However, only a few studies involving relatively small numbers of cases have described their experience of FSA during partial cystectomy. 35 Therefore, the utility of FSA during partial cystectomy remains to be established. In contrast, various recent studies have assessed the consequence of FSA in the status of final surgical margins at the ureters [36] [37] [38] [39] [40] and/or the urethra 36, 38, 41, 42 after radical cystectomy/cystoprostatectomy. A high incidence (e.g. up to 9% 10 ) of marked atypia or CIS at the ureteral margins in radical cystectomy has been reported. As a result, the ureteral margins are often routinely submitted for FSA. Studies for ureteral margins have assessed the accuracy of FSA by comparing with the final histopathology, and have found the sensitivity and specificity of diagnosing CIS at the ureter ranging 45-86% and 95-99%, respectively. 12, 39, 40 In addition, as high as 83% of patients with an initial positive ureteral margin were found to achieve a final negative margin with sequential resection of the ureter. 43 However, more recent studies showed that the rates of negative conversion from initial positive PSA to final negative margins were just 48-53%. 36, 44 Positive FSA diagnosis was also shown to strongly correlate with tumor progression or disease-specific mortality in the univariate setting, but was not an independent risk factor in multivariate models. [39] [40] [41] However, discordance between diagnoses of FSA and the corresponding permanent section showed a trend toward significance (hazard ratio 3.23; P = 0.07) for disease-specific survival. 40 These findings suggest that FSA of the ureteral margins during radical cystectomy is useful for reducing the risk of final positive margins, but not for significantly improving oncological outcomes.
FSA of the distal urethral margin is typically carried out in male patients without prostatic urethral biopsy before cystoprostatectomy. The sensitivity of FSA of the urethral margins ranged from 33% 42 to 92%, 36 whereas the specificity was unvaryingly excellent at 98-99%. 36, 40, 42 Thus, a high false negative rate of FSA diagnosis on the urethral margins is potentially problematic. However, no recent studies have specifically assessed the role of urethral FSA in the status of final surgical margins or the prognosis. A recent retrospective study on the urethral margin attempted to compare between 109 FSA cases and 42 no-FSA cases, both from those who planned to undergo radical cystectomy and orthotopic neobladder reconstruction. 45 Of the FSA cases, just three (2.7%) had a positive FSA, but all these patients, including one who underwent neobladder substitution after having a negative margin on the second FSA, died of bladder cancer. That article did not clearly describe the rates of final positive margin at the urethra between the FSA versus no-FSA groups, but there appears to be a selection bias, because 32 (29.4%) FSA cases versus two (4.8%) no-FSA cases had tumor involving the bladder neck. 45 Kaplan-Meier and log-rank tests further revealed no significant differences in overall survival between patients with negative FSA and no-FSA, but no comparison between those with versus without FSA was made. Therefore, carrying out FSA at the urethral margins is unlikely to be quite beneficial to patients undergoing cystectomy, as long as urethral biopsy is carried out beforehand.
FSA diagnosis of dysplastic changes in the ureteral and urethral margins is often challenging because of histological frozen artifact, as well as associated inflammation, treatment effect and/or cautery artifact. In such challenging cases, pathologists might render a diagnosis of "atypia" (indicating that carcinoma cannot be excluded with certainty). Of 68 FSA diagnoses of atypia at the ureteral or urethral margin, 21 (30.9%) were found to show CIS on the "frozen section control" (i.e. corresponding formalin-fixed previously frozen tissue). 36 In addition, urothelial denudation (i.e. absence of urothelium for evaluation) on non-frozen bladder biopsies is known to occasionally represent high-grade carcinoma where the neoplastic cells have shed as a result of discohesion. 46 The same study showed that FSA diagnosis of denudation in the ureteral or urethral margin was associated with CIS on two (2.0%) of 98 frozen section controls, but could more frequently (15.1%) predict the presence of CIS somewhere else on other submitted ureteral or urethral sections. 36 Accordingly, urologists should be encouraged to obtain additional margins, if feasible, when FSA diagnosis of not only CIS or invasive carcinoma, but also atypia or denudation on the ureteral or urethral tissues is rendered during cystectomy.
FSA of surgical margins during penectomy
Based on my personal experience, intraoperative pathology consultation has often been requested for the assessment of the surgical margin status during penectomy, especially partial resection of the penis for carcinoma. However, a literature search identified few studies focusing on the utility of FSA for resection margins during penectomy. Instead, several review articles have briefly discussed it. 10, 11 Particularly in partial penectomy, these articles recommended FSA of the entire circumference of the amputation margin, because penile cancer can extend through the penile skin, the corpus spongiosum, the corpora cavernosa and the urethral mucosa. In rare cases of perineal Paget's disease that is often multifocal, FSA might also be required. 47 In contrast, FSA of the surgical margins is not usually carried out in total penectomy, but might be requested only for the urethra and surrounding tissue. Thus, no existing literature provides clinical data supporting the usefulness of FSA of the surgical margins during penectomy in reducing positive margin rates or improving oncological outcomes.
FSA during orchiectomy
FSA of the spermatic cord margin during radical orchiectomy is seldom requested, because a positive margin is extremely rare in current practice. However, a partial orchiectomy specimen is occasionally submitted for intraoperative pathology consultation for evaluating surgical margins. More common indications for intraoperative consultation include gross and/or histopathological diagnosis of testicular/paratesticular lesions (e.g. non-neoplastic process, benign neoplasm, teratomatous/ non-teratomatous germ cell tumor, lymphoma), where FSA might contribute to preventing an unnecessary orchiectomy.
Recent studies reported their experience in carrying out FSA on testicular lesions, and showed its high sensitivity or specificity (e.g. 95-100%) for the differential diagnosis of benign and malignant diseases. 48, 49 I also reported a 65-case experience with FSA of biopsy specimens from testicular/paratesticular lesions. 50 Malignant FSA diagnosis resulted in radical orchiectomy in all cases except three with lymphoma and one with "small round blue cell neoplasm" (which was revised to reactive changes on the final diagnosis). Of the 43 cases with non-malignant FSA diagnosis, seven (16.3%) underwent radical orchiectomy mainly because of clinical suspicion for malignancy. Three of the seven cases undergoing orchiectomy despite non-neoplastic or benign diagnosis had fibrous pseudotumor, which is believed to be a reactive lesion, but clinically mimics a malignant neoplasm, 51 because of questionable testicular function and/or a history of severe pain. 52 Overall, in our study, radical orchiectomy was successfully avoided in 36 (83.7%) of 43 cases with benign FSA in addition to three cases of lymphoma. FSA thus appears to be useful for permitting testicular preservation, especially in men with a small, non-palpable, incidentally found mass where there is a much higher likelihood of a benign diagnosis, or another benign lesion where a clinical diagnosis of malignancy is suspected.
Conclusions
Intraoperative pathology consultation often provides critical information for optimal patient care. Despite its wide use, the role of FSA of the surgical margins during urological surgeries in the margin status has not been completely established. Furthermore, current evidence does not strongly support the benefit of routine FSA on surgical margin specimens, especially for improving long-term patient outcomes. Nevertheless, FSA has been shown to reduce the incidence of positive surgical margins, particularly after radical prostatectomy and partial nephrectomy at least in select patients. Meanwhile, surgeons should be aware of not only the precise indications of FSA, but also its limitations. The latter includes suboptimal tissue preparation as a result of histological frozen artifact, cautery artifact or inadequate sampling, any of which might result in an indeterminate or inaccurate diagnosis. Indeed, diagnostic accuracy of FSA is not necessarily extremely high, and is also dependent on the pathologist's knowledge and experience. It should be emphasized that close communication between the submitting surgeon and pathologist is a key to the correct histopathological interpretation of frozen as well as permanent sections. Cost-effectiveness of the FSAs also needs to be considered, because, for instance, in a study from New York University, routine FSA of the urethral margin during prostatectomy was estimated to benefit only a minor portion (20/ 1669; 1.2%) of their patients at an average expense of at least $8640 per patient.
14 Further studies, including randomized prospective trials to minimize selection bias, are warranted to better define the utility of FSA of the surgical margins. A cost-benefit analysis regarding the use of routine FSA during urological surgeries might also be helpful in exploring the economic ramifications of this procedure.
